Untitled Page
Main Menu
Home > Equity > News Analysis > Hot Pursuit
29 March 2020

Hot Pursuit

Prev Next
28-Mar-2020 (17:43)
Delta Corp board approves Rs 125 cr share buyback
28-Mar-2020 (14:20)
Tata Consumer scales down operations due to COVID-19 outbreak
28-Mar-2020 (13:20)
BASF India says Karnataka Appellate Tribunal stayed recovery of tax demand
28-Mar-2020 (12:41)
Graphite India says ICRA reaffirms long term ratings at AA+
Graphite India on Friday (27 March) announced that ICRA has reaffirmed the long term rating for Rs 1,000 crore line of credit for working capital of the company at [ICRA] AA+ (pronounced ICRA double A plus). The outlook on the long term rating has been revised from stable to negative.

Further, ICRA reaffirmed the short term rating for Rs 1,000 crore line of credit for working capital of the company at [ICRA] A1+ (pronounced ICRA A one plus).

Shares of Graphite India rose 4.98% to Rs 118.15 on Friday. The stock has tanked 51% in last one month compared to a 26% fall in benchmark Nifty 50 index in the same period.

On a consolidated basis, Graphite India reported net loss of Rs 353 crore in Q3 December 2019 compared with net profit of Rs 764 crore in Q3 December 2018. Net sales dropped 65.3% to Rs 643 crore in Q3 December 2019 over Q3 December 2018.

Graphite India is engaged in the manufacturing graphite electrodes, graphite equipments, steel, glass reinforced plastic (GRP) pipes and tanks and generation of hydel power. The firm operates through three segments: graphite and carbon, steel and others.


28-Mar-2020 (12:00)
Lupin announces positive CHMP opinion for Nepexto
28-Mar-2020 (10:44)
ICICI Prudential MF hikes stake in PVR
28-Mar-2020 (11:06)
Deepak Fertilisers announces stoppage of production at fertiliser units
28-Mar-2020 (09:42)
HeidelbergCement India says India Ratings affirms ratings at 'IND AA+'
28-Mar-2020 (08:25)
Tata Power Company announces the start of commercial operation of Hydro Power Project JV
28-Mar-2020 (07:53)
Aditya Birla Fashion and Retail announces shut-down due to Novel Coronavirus (COVID-19).
Toll Free number: 1800-425-5501 / 1800-103-5501